Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Disc Medicine heads into the final week of August with a striking disconnect: the stock has climbed 11% over the past month while the CEO has been consistently selling into that strength.
The insider angle is the most concrete story on this name right now. CEO John Quisel sold roughly $2.6 million worth of shares across three transactions on August 17 alone, following earlier sales in July that totalled another $2.5 million. The COO and Chief Legal Officer have also been active sellers through August. The 90-day net figure looks positive at face value — net shares of 153,612 — but the net value figure of $11.4 million reflects a cluster of sales at progressively higher prices, not a buying programme. That pattern, executives lightening up into a rally, is worth tracking against the company's upcoming catalysts.
Short positioning reinforces the cautious read. At nearly 19.5% of the free float, short interest is meaningfully elevated for a biotech of this size — a level that has been climbing, up roughly 10% over the past month to 7.35 million shares. The ORTEX short score has held in a tight band just above 73 all week, ranking in the 9th percentile for short-score rank, which flags this as one of the more heavily watched names on that dimension. Yet the borrow market tells a more relaxed story. Availability is actually quite loose at 327% — roughly 18.8 million shares available against the current short position — and cost to borrow is just 0.56%, barely above flat. There is no squeeze pressure building in the lending market; shorts are well-supplied and cheaply positioned. Options have edged more cautious this week, with the put/call ratio at 0.39 against a 20-day average of 0.31, running about 1.6 standard deviations above the norm, but that is a nudge rather than a structural shift given how far the ratio sits below its 52-week high of 2.61.
The Street remains constructive but divided on timing. HC Wainwright lifted its target to $120 on August 6, maintaining its Buy. Morgan Stanley last moved its Overweight target to $85 in mid-June — now trading above that level at $82.55, the stock has essentially caught up with the more cautious end of the analyst range. The mean target of $101.58 implies roughly 23% upside from here, but that aggregate masks a wide spread: Cantor Fitzgerald held at $125, Wedbush at $88, and Truist at $83 following a sharp trim in February. The bull case centres on the Phase 2 data for selcodebart in myelofibrosis and CKD, with an end-of-Phase 2 FDA meeting targeted before year-end, plus the Roche collaboration and a longer runway toward a potential 2032 sickle cell disease launch. Bears point to the pre-profitability stage — EV/EBITDA is deeply negative at -7.9, PE at -11.7 — and the fact that most key pipeline readouts are still months or years away.
Institutional ownership provides some counterweight to the insider selling. Fidelity (FMR) added 76,000 shares through July, BlackRock added 194,000, and JPMorgan Asset Management built by nearly 497,000 shares in the same period. Vestal Point Capital added 850,000 shares in Q2 — a notable conviction build for a relatively concentrated position at 4% of shares. These flows suggest some large managers are moving in the opposite direction from company insiders, which sets up an interesting tension heading into the next catalyst window.
Disc Medicine's recent earnings track record has been mild: the last four prints produced one-day moves ranging from -0.6% to +4.5%, with the most recent August 7 release generating a modest 1.1% gain. The next event is scheduled for November 6. Between now and then, the FDA end-of-Phase 2 meeting on selcodebart is the data point that matters most — how the market prices that outcome, against a backdrop of heavy insider selling and elevated but well-supplied short interest, is the setup to watch.
See the live data behind this article on ORTEX.
Open IRON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
